Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD
Cell Stem Cell · 2023-10 · 30 (10) · 1299-1314.e9
DOI: 10.1016/j.stem.2023.08.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2023-10. Verfasst von Agnete Kirkeby und 29 weiteren Autor:innen. Beteiligte Einrichtung: Wallenberg Neuroscience Center, Wallenberg Center for Molecular Medicine and Lund Stem Cell Center, Department of Experimental Medical Science, Lund …. Hauptthemen laut MEDLINE: Human Embryonic Stem Cells, Parkinson Disease. Die Arbeit wurde bisher 160-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Knut and Alice Wallenberg Foundation, Swedish Research Council.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wallenberg Neuroscience Center, Wallenberg Center for Molecular Medicine and Lund Stem Cell Center, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden; Novo Nordisk Foundation Center for St…
- Wallenberg Neuroscience Center, MultiPark and Lund Stem Cell Center, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden.
- Department of Neurosurgery, Skåne University Hospital, 221 85 Lund, Sweden.
- Cell Therapy R&D, Novo Nordisk A/S, 2760 Måløv, Denmark.
- Wallenberg Neuroscience Center, Wallenberg Center for Molecular Medicine and Lund Stem Cell Center, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden; Wallenberg Neuroscience Center, Multi…
- Department of Nuclear Medicine & PET-Center and Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.
Förderung
- Medical Research Council
- Knut and Alice Wallenberg Foundation
- Swedish Research Council
- New York Stem Cell Foundation
- Lundbeck Foundation
- European Union
- Novo Nordisk Foundation
- Novo Nordisk A/S
Zitieren
APA
Kirkeby, A., Nelander, J., Hoban, D. B., Rogelius, N., Bjartmarz, H., Novo Nordisk Cell Therapy R&D, Storm, P., Fiorenzano, A., Adler, A. F., Vale, S., Mudannayake, J., Zhang, Y., Cardoso, T., Mattsson, B., Landau, A. M., Glud, A. N., Sørensen, J. C., Lillethorup, T. P., Lowdell, M., …, & Parmar, M. (2023). Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD. Cell Stem Cell, 30(10), 1299-1314.e9. https://doi.org/10.1016/j.stem.2023.08.014
Vancouver
Kirkeby A, Nelander J, Hoban DB, Rogelius N, Bjartmarz H, Novo Nordisk Cell Therapy R&D, et al. Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD. Cell Stem Cell. 2023;30(10):1299-1314.e9. doi:10.1016/j.stem.2023.08.014
BibTeX
@article{Kirkeby2023,
author = {Kirkeby, Agnete and Nelander, Jenny and Hoban, Deirdre B and Rogelius, Nina and Bjartmarz, Hjálmar and Novo Nordisk Cell Therapy R&D, Novo Nordisk Cell Therapy R&D and Storm, Petter and Fiorenzano, Alessandro and Adler, Andrew F and Vale, Shelby and Mudannayake, Janitha and Zhang, Yu and Cardoso, Tiago and Mattsson, Bengt and Landau, Anne M and Glud, Andreas N and Sørensen, Jens C and Lillethorup, Thea P and Lowdell, Mark and Carvalho, Carla and Bain, Owen and van Vliet, Trinette and Lindvall, Olle and Björklund, Anders and Harry, Bronwen and Cutting, Emma and Widner, Håkan and Paul, Gesine and Barker, Roger A and Parmar, Malin},
title = {Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD},
journal = {Cell Stem Cell},
year = {2023},
volume = {30},
number = {10},
pages = {1299--1314.e9},
doi = {10.1016/j.stem.2023.08.014}
}
EUVIMED